Oxidative Stress and Its Relation to Lower Urinary Tract Symptoms
Andersson, Karl Erik LU
(2022)
In International Neurourology Journal
26(4).
p.261-267
- Abstract
The aim of this review is to discuss how to link lower urinary tract symptoms (LUTS) and oxidative stress (OS) and to define relevant targets for therapeutic intervention. Narrative review based on published literature. Many of the multifactorial pathophysiological mechanisms behind LUTS can initiate reactive oxygen species (ROS) generation. Assuming that OS is a consequence rather than a primary cause of LUTS it seems reasonable to identify both the disease mechanism initiating LUTS, and the source of ROS involved. There are many possible sources of ROS overproduction, but the NADPH oxidase (NOX) family of enzymes is the primary source; NOX activation in turn, may result in the activation of secondary ROS sources, i.e., ROS-dependent... (More)
The aim of this review is to discuss how to link lower urinary tract symptoms (LUTS) and oxidative stress (OS) and to define relevant targets for therapeutic intervention. Narrative review based on published literature. Many of the multifactorial pathophysiological mechanisms behind LUTS can initiate reactive oxygen species (ROS) generation. Assuming that OS is a consequence rather than a primary cause of LUTS it seems reasonable to identify both the disease mechanism initiating LUTS, and the source of ROS involved. There are many possible sources of ROS overproduction, but the NADPH oxidase (NOX) family of enzymes is the primary source; NOX activation in turn, may result in the activation of secondary ROS sources, i.e., ROS-dependent ROS production. Selective NOX inhibition therefore seems an attractive therapeutic strategy in LUTS treatment. The finding of NOX2 localization to centers in the brain associated with micturition control, opens up for further studies of NOX involvement in the central control of micturition, normally and in disease. Further information on the localization of the different isoforms of NOX in the LUT e.g., the bladder wall and its components and the prostate, is desirable. To optimize treatment, the pathophysiological mechanism initiating LUTS, and the activated isoform of NOX, should be identified. Unfortunately, in most cases of LUTS this is currently not possible. Even if selective NOX inhibitors have entered the clinical trial stage for treatment of disorders other than LUT dysfunction, their efficacy for LUTS treatment has to be demonstrated. If this can be achieved, an attractive approach would be combination of selective NOX inhibition with established drug therapies.
(Less)
- author
- Andersson, Karl Erik
LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Micturition control, NADPH oxidases, Reactive oxygen species, Treatment
- in
- International Neurourology Journal
- volume
- 26
- issue
- 4
- pages
- 7 pages
- publisher
- Korean Association of Medical Journal Editors
- external identifiers
-
- scopus:85146303570
- ISSN
- 2093-4777
- DOI
- 10.5213/INJ.2244190.095
- language
- English
- LU publication?
- yes
- id
- fb597ca0-9509-48dc-971c-7cad878003e9
- date added to LUP
- 2023-02-15 15:48:49
- date last changed
- 2023-02-15 15:48:49
@article{fb597ca0-9509-48dc-971c-7cad878003e9,
abstract = {{<p>The aim of this review is to discuss how to link lower urinary tract symptoms (LUTS) and oxidative stress (OS) and to define relevant targets for therapeutic intervention. Narrative review based on published literature. Many of the multifactorial pathophysiological mechanisms behind LUTS can initiate reactive oxygen species (ROS) generation. Assuming that OS is a consequence rather than a primary cause of LUTS it seems reasonable to identify both the disease mechanism initiating LUTS, and the source of ROS involved. There are many possible sources of ROS overproduction, but the NADPH oxidase (NOX) family of enzymes is the primary source; NOX activation in turn, may result in the activation of secondary ROS sources, i.e., ROS-dependent ROS production. Selective NOX inhibition therefore seems an attractive therapeutic strategy in LUTS treatment. The finding of NOX2 localization to centers in the brain associated with micturition control, opens up for further studies of NOX involvement in the central control of micturition, normally and in disease. Further information on the localization of the different isoforms of NOX in the LUT e.g., the bladder wall and its components and the prostate, is desirable. To optimize treatment, the pathophysiological mechanism initiating LUTS, and the activated isoform of NOX, should be identified. Unfortunately, in most cases of LUTS this is currently not possible. Even if selective NOX inhibitors have entered the clinical trial stage for treatment of disorders other than LUT dysfunction, their efficacy for LUTS treatment has to be demonstrated. If this can be achieved, an attractive approach would be combination of selective NOX inhibition with established drug therapies.</p>}},
author = {{Andersson, Karl Erik}},
issn = {{2093-4777}},
keywords = {{Micturition control; NADPH oxidases; Reactive oxygen species; Treatment}},
language = {{eng}},
number = {{4}},
pages = {{261--267}},
publisher = {{Korean Association of Medical Journal Editors}},
series = {{International Neurourology Journal}},
title = {{Oxidative Stress and Its Relation to Lower Urinary Tract Symptoms}},
url = {{http://dx.doi.org/10.5213/INJ.2244190.095}},
doi = {{10.5213/INJ.2244190.095}},
volume = {{26}},
year = {{2022}},
}